anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The serum elimination half-life is approximately 5–6 hours and the total clearance is around 35 L/hr. After intravenous administration, approximately 50% to 70% of the dose is excreted in the urine as unchanged drug. Following a 200-mg I.V. dose, concentrations in the urine usually exceed 200 mcg/mL 0–2 hours after dosing and are generally greater than 15 mcg/mL 8–12 hours after dosing. Following a 400-mg I.V. dose, urine concentrations generally exceed 400 mcg/mL 0–2 hours after dosing and are usually greater than 30 mcg/mL 8–12 hours after dosing. The renal clearance is approximately 22 L/hr. The urinary excretion of ciprofloxacin is virtually complete by 24 hours after dosing.

Although bile concentrations of ciprofloxacin are several fold higher than serum concentrations after intravenous dosing, only a small amount of the administered dose (<1%) is recovered from the bile as unchanged drug. Approximately 15% of an I.V. dose is recovered from the feces within 5 days after dosing.
The present disclosure involves a medical system that includes one or more implantable medical devices configured to deliver a medical therapy to a patient. The medical system also includes a portable electronic device on which a touch-sensitive user interface is implemented. The user interface is configured to provide a visual representation of the medical therapy through a hierarchy. The hierarchy includes a lower level representation of the medical therapy that corresponds to a stimulation program that includes a plurality of configurable stimulation parameters. The hierarchy includes a middle level representation of the medical therapy that corresponds to a stimulation program-set that includes a plurality of different stimulation programs. The hierarchy includes an upper level representation of the medical therapy that corresponds to a scrollable collection of stimulation program-sets that are represented by a plurality of digital cards, respectively.
PURPOSE: We sought to assess associations between health-related quality of life (QOL), bladder-related QOL, bladder symptoms, and bladder catheterization route among adolescents and young adults with spina bifida.
MATERIALS AND METHODS: Clinical questionnaires administered to individuals ≥ 12 years old requiring catheterization between June 2019 to March 2020 in a spina bifida center were retrospectively analyzed. Questionnaires were completed in English or Spanish independently or with caregiver assistance. Medical records were reviewed for demographic and clinical characteristics. Primary exposure was catheterization route (urethra or channel). Primary outcome was health-related QOL, measured by Patient-Reported Outcomes Measurement Information System Pediatric Global Health 7 (PGH-7). Secondary outcomes were bladder-related QOL and bladder symptoms, measured by Neurogenic Bladder Symptom Score (NBSS). Nested, multivariable linear regression models assessed associations between catheterization route and questionnaire scores.
RESULTS: Of 162 patients requiring catheterization, 146 completed both the PGH-7 and NBSS and were included. Seventy-three percent were catheterized via urethra and 27% via channel. Median age was 17.5 years (range 12-31), 58% of patients were female, and 80% had myelomeningocele. Urinary incontinence was more common among those who catheterized via urethra (60%) compared to channel (33%). On adjusted analyses, catheterization route was not significantly associated with PGH-7 or NBSS bladder-related QOL scores. More bladder symptoms were associated with worse bladder-related QOL. Patients who catheterized via channel had fewer bladder symptoms than those who catheterized via urethra.
CONCLUSIONS: Catheterization route was not significantly associated with QOL. Though catheterization via channel was associated with fewer bladder symptoms, only degree of current bladder symptoms was significantly associated with bladder-related QOL.
The assessment of LVDD is routinely included in echocardiographic evaluation because it correlates with cardiac disease progression and its prognostic value. Classic parameters used for assessing LV diastolic function correlate well with invasive measurements which remains the gold standard. Nevertheless, no one echocardiographic parameter alone can completely evaluate LVDD. LV diastolic function evaluation in atrial fibrillation is still challenging, since the E/A ratio, one of the most used parameters in echocardiographic evaluation, cannot be feasible. This is not a good reason to give up measurement. In this review, we analyze the different methods for estimating LV diastolic function in atrial fibrillation, including measurement not dependent on atrial systole and some novel methods that are promising, but not ever available during clinical practice highlighting that this assessment is mandatory for a complete clinical evaluation of the patients.
BACKGROUND: Gouty arthritis is a metabolic condition caused by disordered purine metabolism and elevated uric acid levels. This study adopts a bibliometric approach to analyze current research on pain in gouty arthritis and forecast future research trends.
METHODS: Retrieve relevant research on gouty arthritis pain in the Web of Science core collection database, screen literature, and use visualization software such as CiteSpace, Vosviewers, and R package "Bibliometrix" for analysis.
RESULTS: The total number of documents included was 1133, with 909 articles and 224 reviews. Between 2014 and 2024, there was an overall upward trend in the number of publications about pain in gouty arthritis, with the United States of America and China ranking first and second, respectively, in terms of publication volume. The UNIVERSITY OF ALABAMA BIRMINGHAM had the most publications, and Professor DALBETH N played a key role in this field. According to the keyword analysis, disease management and treatment, particularly methods for enhancing patients' quality of life and reducing symptoms, are research hotspots. For a deeper understanding, attention is also being paid to the epidemiology and pathological mechanisms of the disease. Emerging keywords such as "gut microbiota" and "urate-lowering therapies" indicate growing interest in the interrelationship between gut microbiota and gout, and the development of new treatment methods.
CONCLUSION: This bibliometric study reveals that research on gouty arthritis pain is actively developing. Current hot topics reflect investigations into the deeper pathological mechanisms of gouty arthritis and the development of new treatment methods, including urate-lowering therapies. There is also increasing attention on the role of gut microbiota in the disease. Despite limitations such as the preliminary nature of research methods and insufficient interdisciplinary collaboration, future research directions aim to improve the rigor of research design, strengthen international cooperation, promote unified treatment guidelines, and optimize the diagnosis and treatment of gouty arthritis with new technologies like artificial intelligence, precision medicine, and nanomedicine. This will drive the field towards a deeper scientific understanding, more effective treatment methods, and more comprehensive disease management, ultimately improving patients' prognosis and quality of life.
Introduction: Cluster analysis can classify without a priori assumptions the heterogeneous chronic lower airway diseases found in former workers at the World Trade Center (WTC) disaster site. Methods: We selected the first available chest computed tomography scan with quantitative computed tomography measurements on 311 former WTC workers with complete clinical, and spirometric data from their closest surveillance visit. We performed a nonhierarchical iterative algorithm K-prototype cluster analysis, using gap measure. Results: A five-cluster solution was most satisfactory. Cluster 5 had the healthiest individuals. In cluster 4, smoking was most prevalent and intense but there was scant evidence of respiratory disease. Cluster 3 had symptomatic subjects with reduced forced vital capacity impairment (low FVC). Clusters 1 and 2 had less dyspneic subjects, but more functional and quantitative computed tomography evidence of chronic obstructive pulmonary disease (COPD) in cluster 1, or low FVC in cluster 2. Clusters 1 and 4 had the highest proportion of rapid first-second forced expiratory volume decliners. Conclusions: Cluster analysis confirms low FVC and COPD/pre-COPD as distinctive chronic lower airway disease phenotypes on long-term surveillance of the WTC workers.
Undergraduate peer-facilitators part of a curricular kinesiology program will facilitate a personalized group-based exercise program adapted to the participant's abilities, teach participants how to exercise, and gauge exercise intensity in a safe manner (26). The CANMAT guidelines will be implemented, with the program consisting of supervised group-based moderate-intensity exercise sessions lasting 30-minutes (plus 10-minutes for warm-up and cool-down), 3 times weekly, for a period of 10-weeks. Participants will start exercising at a low intensity and progressively increase until they are consistently exercising at a moderate intensity. As a result of the uncertainty surrounding the pandemic, the intervention will be conducted either via a virtual platform or in-person at the Exercise and Health Psychology Lab, depending on the health and safety restrictions applicable to when the student enrolls and begins their program.
That group will be formed by the 40 patients who underwent mandatory repeat EPS 8-10 weeks following contact force guided PVI in the PRESSURE study (ClinicalTrials.gov Identifier: NCT01942408). RFA ablation data from reference group (Contact Force Group) will be compared with those obtained from the Ablation Index Group.
Chronic kidney disease (CKD) inevitably progresses to end-stage renal disease if intervention does not occur timely. However, there are limitations in predicting the progression of CKD by solely relying on changes in renal function. A biomarker with high sensitivity and specificity that can predict CKD progression early is required. We used the online Gene Expression Omnibus microarray dataset GSE45980 to identify differentially expressed genes (DEGs) in patients with progressive and stable CKD. We then performed functional enrichment and protein-protein interaction network analysis on DEGs and identified key genes. Finally, the expression patterns of key genes were verified using the GSE60860 dataset, and the receiver operating characteristic curve analysis was performed to clarify their predictive ability of progressive CKD. Ultimately, we verified the expression profiles of these hub genes in an in vitro renal interstitial fibrosis model by real-time PCR and western blot analysis. Differential expression analysis identified 50 upregulated genes and 47 downregulated genes. The results of the functional enrichment analysis revealed that upregulated DEGs were mainly enriched in immune response, inflammatory response, and NF-κB signaling pathways, whereas downregulated DEGs were mainly related to angiogenesis and the extracellular environment. Protein-protein interaction network and key gene analysis identified CCR7 as the most important gene. CCR7 mainly plays a role in immune response, and its only receptors, CCL19 and CCL21, have also been identified as DEGs. The receiver operating characteristic curve analysis of CCR7, CCL19, and CCL21 found that CCR7 and CCL19 present good disease prediction ability. CCR7 may be a stable biomarker for predicting CKD progression, and the CCR7-CCL19/CCL21 axis may be a therapeutic target for end-stage renal disease. However, further experiments are needed to explore the relationship between these genes and CKD.
Echocardiography strain measurement performed taking about 10 minutes. After resting strain measurement done, first set of nuclear images performed. Once these images are completed, participant given Regadenoson 0.4 mg by vein over about 10 seconds. Within 2 to 4 minutes of receiving the Regadenoson, measurements repeated. These measurements will take about 2 minutes to complete.
FIELD: production of free-flowing powder containing particles of carrier material with coating; may be used in various branches of national economy. SUBSTANCE: used for particle coating is spray drier or spray cooled with means for spraying in the form of high-pressure spraying nozzle or spraying wheel. The method provides for creation of flow of droplets of liquid coating, supply of transporting gas with particles to be coated, and supply of drying gas to drying chamber. Contact of coating material with particles to be coated is effected so as to prevent premature contact of drying gas with coating material. EFFECT: higher efficiency. 18 cl, 4 dwg, 1 tbl
PROBLEM TO BE SOLVED: To provide a cosmetic pack sheet capable of significantly reducing the time and effort for skin care.SOLUTION: This cosmetic pack sheet includes a gel layer, and this gel layer has a matrix made of a gel body having a melting point of 15°C or higher and 40°C or lower and an effective constituent for cosmetic contained in the matrix. Preferably, the cosmetic pack sheet includes only the gel layer. Preferably, gelatin is used as a gelling agent of the gel body. Preferably, the average molecular weight of the gelatin is 5,000 or more and 60,000 or less. Preferably, the gel layer is a laminated body consisting of a plurality of micro layers. Preferably, the plurality of micro layers contain different effective constituents for cosmetic. Preferably, skin lotion constituent, beauty liquid constituent, and milky lotion constituent are used as the effective constituents for cosmetic, and the plurality of micro layers contain the skin lotion constituent, beauty liquid constituent, and milky lotion constituent in that order from the inside.
The PRESENT cohort is set up according to the 'cohort multiple Randomised Controlled Trial' design. The basis of this design is a prospective cohort of patients with bone metastases, receiving care as usual, who give informed consent for cohort participation. At the UMC Utrecht, patients are furthermore asked for informed consent to be randomized in future RCTs conducted within the cohort. Patients are informed that they will be offered the experimental intervention if they are randomly selected. They are also informed that they otherwise might serve as controls without being notified and that their data can be used in a trial context. For each patient in the cohort, clinical and patient-reported outcomes are captured at baseline and at regular intervals during follow-up. Within this cohort, multiple RCTs can be conducted. For this purpose, eligible patients who have provided the consent required for them to participate in an RCT within the cohort are identified. From this subcohort, a random selection of patients will be invited to undergo the experimental intervention. Eligible participants who were not randomly selected receive standard care, are not informed about the experimental intervention and serve as controls. Outcomes in this control group are compared with the outcomes of those who were offered the experimental intervention, in order to estimate the effect of the experimental intervention versus usual care. Within the cohort, the same process can be repeated for trials of other interventions.
PURPOSE: To obtain a detergent compsn. which is lowly irritative, is excellent in foaming power and foam quality, and gives a good feeling of refreshment during rinsing and after cleaning. CONSTITUTION: This detergent compsn. contains an N-alkyl or -alkenylcitramide represented by the formula (wherein R is a 10-20C satd. or unsatd. hydrocarbon group; and M is H, an alkali or alkaline earth metal, ammonium, or an alkanolamine) and at least one surfactant selected from among an amphoteric surfactant, an amine oxide, and an anionic surfactant other than the above- mentioned amide and a higher fatty acid salt.
A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.
Pathologically confirmed stage II/III rectal adenocarcinoma patients who received neoadjuvant chemoradiotherapy followed by a clinical complete response from the year 2010 to 2018 were included. Sequential subjects were identified from a prospective maintained database in the Sun Yat-sen University Cancer Center. Clinical experts on rectal cancer from other 5 regional medical centers in China were also invited to participate, and provided data of cCR patients. Standardized forms for data collection were sanded to researchers in each center. Patients received radical resection will constituted our surgery group. Those refused surgery constituted the observation group who went on with the watch and wait approach. A propensity-score matched observational analysis will be used to compare the oncological outcome of these two groups.
Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 2 doses of Prevnar™ vaccine at Months 0 and 2 and 1 dose of Hiberix® vaccine at Month 1 in the Primary NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
BACKGROUND: Hernioplasty is one of the most commonly performed surgeries. However, the optimal procedure for young adults has not been defined yet. Our study compared the outcomes of laparoscopic percutaneous extraperitoneal closure (LPEC) in young adults with outcomes in children.
MATERIAL AND METHODS: We retrospectively reviewed patients aged 0-30 years who underwent LPEC. Data regarding age, sex, hernia type, surgical time, pre-intraoperative laterality, contralateral patent processus vaginalis (CPPV), and complications were analyzed.
RESULTS: LPEC was performed on 2642 patients in our hospital. Of these, 51 patients were young adults (aged 15-30 years). Asymptomatic CPPV in unilateral patients was frequent in the <15-year age group (50.2%) compared to the 15-30-year age group (15.9%). The median surgical time was shorter in the <15-year age group (19 min, interquartile range [IQR]: 24-33) compared to that of the 15-30-year age group (33 min, IQR: 23.3-40.8).
CONCLUSIONS: This is the first report on the outcomes in young adult patients who underwent LPEC. The median surgical time was longer in the 15-30-year age group than in the <15-year age group. The median follow-up was 4.7 years with no intra-postoperative complications, such as postoperative bleeding, infection, persistent pain, and recurrence. LPEC is an effective, cosmetic, and safe surgical treatment in young adults and children.
This study is a prospective, randomized, single-blind crossover study intended to enroll patients who are implanted or are scheduled to be implanted with a Biotronik CLS and accelerometer capable CRT-D device. Patients will serve as their own control group with regard to modes of rate-adaptive pacing. Patients with a previously implanted Biotronik CRT-D device with CLS-capability will be recruited from health care institutions in San Diego and all dedicated functional testing will be performed at the University of California, San Diego (UCSD). The goal enrollment target for analysis will be 15 patients, with up to 20 patients enrolled to allow for withdrawals.

The purpose of this study is to evaluate whether changes to an implanted ICD can improve the functional status of patients with suspected chronotropic incompetence (CI). CI is a condition in which the heart rate is unable to adequately respond to meet the patient's physical demands, such as walking, climbing stairs, or doing household chores. CI is common in patients with cardiovascular disease, particularly in patients with heart failure. Common clinical management of patients with suspected CI is to activate an accelerometer setting in the cardiac resynchronization therapy with defibrillator (CRT-D) device. An accelerometer will adjust the heart rate to fit the physiological circumstances and needs of the patient based on patient movement only. BIOTRONIK is a company that has developed a novel technology included in the settings for CRT-D devices that offers CLS as an alternative to a standard accelerometer. CLS utilizes sensed electrical properties of the heart in order to assess what may be the best heart rate for both physical and mental demands. This study is designed to compare whether patients will benefit from CLS when compared with standard accelerometer technology.
A system and method for determining kinetic parameters associated with a kinetic model of an imaging agent in a liver is provided. An image reconstruction device can receive radiotracer activities corresponding to a predetermined time period. For example, these radiotracer activities can include PET scan data corresponding to a number of time frames. The radiotracer activities can be used to determine a liver time activity curve and a circulatory input function. The liver time activity curve and circulatory input function can be used along with a kinetic model of the liver to produce kinetic parameters. These kinetic parameters can be used to determine hepatic scores, such as a hepatic steatosis score, a hepatic inflammation score, and a cirrhosis score. These scores are indicative of diseases of the liver, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and hepatic fibrosis.
Pharmaceutical compsn. includes as active ingredient a lysine salt of formula (I), each component being in racemic or either optically active form. The compsns. can be administered orally, parenterally, by aerosol or as a suppository. The salt (+-) lysine (-) carboxymethylcysteinate (Ia) is new. (I) are made by reacting carboxymethylcysteine, or its alkali or alkaline earth salts, with lysine, or its acid addition salt, opt. in the presence of a solvent. The salts have mucolytic, bronchosecretolytic and antibronchospastic activities. Their bioavailbility or degree of assimulation is superior to that of the parent cpds., so they provide elevated blood levels.
A therapeutic agent or composition is obtained by heating a mixture of a "sulpha" drug and elementary iodine until the evolution of fumes of iodine ceases.  The sulpha drugs consist of sulphanilamide and its derivatives such as sulphapyridine, sulphathiazole, sulphapyrazine, sulphaguanidine and sulphadiazine, including their salts and substitution products such as sulphanilamide phosphate and sulpha-methyl-diazines.  The heating step may be effected at a temperature of 40-80 DEG  C., according to one example in the presence of alcohol.  The product of the heating step is preferably digested with alcohol or other solvent which will dissolve iodine or the sulpha drug containing adsorbed iodine, but is a poor solvent for the sulpha drug itself. The separated solution (fraction "A") is evaporated to dryness and treated with a selected solvent for free iodine such as petroleum ether to remove unadsorbed elementary iodine.  The undissolved extraction residue (fraction "B") is washed with alcohol or other solvent for free iodine.  Both fractions retain the gross physical and chemical characteristics of the sulpha drugs, but have enhanced antibacterial potency brought about by an obscure chemical change.  Fraction "A" contains adsorbed iodine. Fraction "B" is free from iodine.